** Shares of Mesoblast MSB.AX fall as much as 9.3% to A$2.55, their largest intraday pct loss since Dec 20
** Stock hits lowest level since Dec 24
** The drug developer completes private placement to raise A$260 mln ($160.73 mln)
** Placement issue price at A$2.5 per share, representing an 11% discount to stock's last close
** Co says funds to be used for the U.S. commercial launch of its Ryoncil therapy for the treatment of graft-versus-host disease, among others
** Stock down 15.2% YTD, including current session's moves
($1 = 1.6176 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.